Stocktoria
Anebulo Pharmaceuticals, Inc. ANEB
Anebulo Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $4.3M | $3.5M | $5.6M | $3.0M | $2.3M |
| Operating income | -$9.2M | -$8.3M | -$11.8M | -$6.8M | -$3.6M |
| Interest expense | $400,000 | $200,000 | — | — | $11,767 |
| Net income | -$8.5M | -$8.2M | -$11.7M | -$6.8M | -$30.3M |
| EPS (diluted) | $-0.25 | $-0.32 | $-0.47 | $0.29 | — |
| Operating cash flow | -$6.3M | -$8.1M | -$9.7M | -$5.4M | -$4.9M |
| Cash & equivalents | $11.6M | $3.1M | $11.2M | — | — |
| Total assets | $12.1M | $4.1M | $11.7M | $15.6M | $21.7M |
| Total liabilities | $487,688 | $260,583 | $1.1M | $512,531 | $241,633 |
| Shareholders' equity | $11.7M | $3.8M | $10.6M | $15.1M | $21.4M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| EPS growth | — | — | -262.1% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.